Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
292 studies found for:    (ARISE)
Show Display Options
Rank Status Study
1 Recruiting Arise: An Online Relapse Prevention Tool for Adolescent Substance Abusers
Condition: Substance-Related Disorders
Intervention: Behavioral: Arise
2 Recruiting Aortic Replacement Using Individualised Regenerative Allografts - ARISE (the "Surveillance")
Condition: Heart Valve Disease
Intervention: Other: Decellularized human heart valves
3 Recruiting ARISE: After 8 Hours Reperfusion in Ischemic Stroke Embolization
Condition: Ischemic Stroke
Intervention: Device: mechanical thrombectomy
4 Recruiting Assessment of Tecfidera® in Radiologically Isolated Syndrome (RIS)
Condition: Multiple Sclerosis (MS)
Interventions: Drug: Tecfidera;   Drug: Placebo
5 Completed Effectiveness of Inelastic LSO Versus Standard Medical Treatment for Back Pain Associated With Kyphosis
Conditions: Kyphosis;   Back Pain
Intervention: Other: Summit 456 TLSO
6 Unknown  Australasian Resuscitation In Sepsis Evaluation Randomised Controlled Trial
Condition: Severe Sepsis
Intervention: Other: Early Goal Directed Therapy (EGDT)
7 Unknown  Effect of Atorvastatin Versus Rosuvastatin Intensive Statin Regimens on Chinese Elderly Patients Undergoing PCI
Condition: Focus of Study
Interventions: Drug: Atorvastatin;   Drug: Rosuvastatin
8 Active, not recruiting Study to Evaluate the Efficacy and Safety of AMG 334 Compared to Placebo in Migraine Prevention
Condition: Migraine
Interventions: Drug: AMG 334;   Drug: Placebo
9 Active, not recruiting Analysis of Revascularisation in Ischemic Stroke With EmboTrap
Condition: Ischemic Stroke
Intervention: Device: EmboTrap® Revascularization Device
10 Completed AngioSeal Versus Radial Approach in Acute Coronary Syndrome
Condition: Acute Coronary Syndrome
Intervention: Device: Percutaneous coronary intervention
11 Completed Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome: ARISE-1
Condition: Dry Eye Syndrome
Interventions: Drug: RGN-259;   Drug: Placebo
12 Recruiting Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome : ARISE-2
Condition: Dry Eye Syndrome
Interventions: Drug: RGN-259;   Drug: Placebo
13 Recruiting Vascular Closure Device Versus Transradial Approach in Primary Percutaneous Coronary Intervention
Conditions: Myocardial Infarction;   Complications; Device, Vascular;   Injury of Radial Artery;   Injury; Blood Vessel, Femoral, Artery
Interventions: Procedure: Transradial primary percutaneous coronary intervention;   Procedure: Transfemoral primary percutaneous coronary intervention
14 Unknown  ARISE – Aggressive Reduction of Inflammation Stops Events
Conditions: Atherosclerosis;   Coronary Artery Disease;   Myocardial Infarction;   Unstable Angina
Intervention: Drug: AGI-1067
15 Completed
Has Results
Assessment of Rituximab's Immunomodulatory Synovial Effects (The ARISE Study)
Condition: Rheumatoid Arthritis
Intervention: Drug: rituximab
16 Recruiting Analysis of Revascularization in Ischemic Stroke With EmboTrap
Conditions: Stroke;   Ischemia
Intervention: Device: EmboTrap® Revascularization Device
17 Active, not recruiting
Has Results
A Multicenter Study of SBC-102 (Sebelipase Alfa) in Patients With Lysosomal Acid Lipase Deficiency/ ARISE (Acid Lipase Replacement Investigating Safety and Efficacy)
Conditions: Cholesterol Ester Storage Disease (CESD);   Lysosomal Acid Lipase Deficiency
Interventions: Drug: SBC-102 [sebelipase alfa] (1 mg/kg);   Drug: Placebo
18 Completed
Has Results
Imatinib in Patients With Mucosal or Acral/Lentiginous Melanoma
Conditions: Mucosal Melanoma;   Acral/Lentiginous Melanoma;   Chronically Sun Damaged Melanomas
Intervention: Drug: Imatinib
19 Completed Does Capnography Prevent Hypoxemia During Endoscopic Retrograde Cholangiopancreatography and Endoscopic Ultrasound?
Condition: Hypoxemia
Interventions: Device: Capnography (Specific device name: Capnostream 20);   Device: Sham
20 Completed ROsuvastatin Pretreatment to Reduce MyocArdial Periprocedural Necrosis:Comparison With Atorvastatin Reloading
Condition: Assess the Periprocedural Myocardial Necrosis
Interventions: Drug: ATORVASTATIN 80 mg;   Drug: ROSUVASTATIN 40 mg

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.